EyeTechCare has secured ?10 million in a third round of funding for two international clinical trials for the EyeOP1 glaucoma treatment.
EyeTechCare has secured €10 million in a third round of funding for two international clinical trials for the EyeOP1 glaucoma treatment.
The firm, which develops non-invasive therapeutic medical devices for the ophthalmology market, plans to use the funds to complete the EyeMUST 2 international trial. The results are due to be published in 2014 and the company will be able to fund the FDA registration process.
Mr Bernard Chauvin, MD of EyeTechCare and private investor, stated, "The simplicity of EyeOP1 comes from an uncomplicated yet brilliant idea: the use of ultrasound to treat glaucoma. Beyond the complex technical constraints, which have been incredibly well managed, there is a team with the desire to achieve their goal of helping patients."
"Quite simply, the results are there," continued Mr Chauvin, "I am proud to be associated with what is real therapeutic progress, particularly as it fits so well with my vocation as a doctor and an entrepreneur."
Alex Perouse, co-head of venture capital activity at Omnes Capital, added, "We've been excited by EyeTechCare's market positioning right from the start. The arrival of this new investor will support the growth of the business. The company's prospects for development are very encouraging and the team in place has always been able to meet its self-imposed deadlines."